| Literature DB >> 28545467 |
Anna Serroni1,2, Chiara Francesca Magistrali1, Giovanni Pezzotti1, Luca Bano3, Martina Pellegrini1, Giulio Severi1, Chiara Di Pancrazio4, Mirella Luciani4, Manuela Tittarelli4, Silvia Tofani1, Antonio De Giuseppe5.
Abstract
BACKGROUND: Clostridium perfringens is an important animal and human pathogen that can produce more than 16 different major and minor toxins. The beta-2 minor toxin (CPB2), comprising atypical and consensus variants, appears to be involved in both human and animal enterotoxaemia syndrome. The exact role of CPB2 in pathogenesis is poorly investigated, and its mechanism of action at the molecular level is still unknown because of the lack of specific reagents such as monoclonal antibodies against the CPB2 protein and/or the availability of a highly purified antigen. Previous studies have reported that purified wild-type or recombinant CPB2 toxin, expressed in a heterologous system, presented cytotoxic effects on human intestinal cell lines. Undoubtedly, for this reason, to date, these purified proteins have not yet been used for the production of monoclonal antibodies (MAbs). Recently, monoclonal antibodies against CPB2 were generated using peptides designed on predicted antigenic epitopes of this toxin.Entities:
Keywords: Atoxic rCPB2Δ1–25-His6; Monoclonal antibody; Ni2+ affinity chromatography
Mesh:
Substances:
Year: 2017 PMID: 28545467 PMCID: PMC5445335 DOI: 10.1186/s12934-017-0707-8
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 1Comparison of the amino acid sequence of the protein β2 between the atypical isoforms 6069 and 6157. The mutation changes in the amino acid sequence between the two proteins are highlighted in yellow
Fig. 2Recombinant atypical beta2 toxin characterization by Western blotting using anti-His C-Term MAb. The supernatant of recombinant atypical β2 toxins 6157 and 6069, full-length forms (lanes 1 and 2), the cellular lysate of recombinant atypical β2 toxins 6157 and 6069, deleted forms (lanes 3 and 4). The molecular weight standard is on the right
Fig. 3SDS-PAGE and Coomassie gel staining of purified recombinant rCPB2Δ1–25-His6. Purified recombinant rCPB2Δ1–25-His6 elution fractions (lanes 2–6 and 11–15); BSA standards, 1 μg (lane 7), 2 μg (lane 8) and 5 µg (lane 9); molecular weight standard (lanes 1 and 10)
Fig. 4Characterization of monoclonal antibodies. Each MAb was tested against rCPB2Δ1–25-His6 (first lanes) and wild-type CPB2 protein (second lanes) produced by Clostridium perfringens using the immunoblotting assay
Fig. 5MAbs characterization by ELISA. MAbs 5B4F11, 4E10E10, 5C11E6, 4E10F8 (a), 23E6C8 (b) and 23E6E6 (c) were analysed using wild-type atypical toxin rCPB2Δ1–25-His6 and consensus CPB2 proteins
Nucleotide sequences of the primers used for the amplification of the full-length and deleted forms of CPB2 toxin
The restriction sites are underlined with a solid line, and ATG start codons are in bold